Table 1. Published KETO and MDZ Data Sets.
| Sources | dose (mg) |
sample size per subject (time frame) |
Size (M/F) |
meal |
|---|---|---|---|---|
| KETO | ||||
| (Gascoigne 1981) | 200 capsule | 5(1 – 24h) | 3(N/A) | fasting |
| 200 solution | 5(1 – 24h) | 3(N/A) | fasting | |
| 100,200,400 tablet | 8(0.5-48h) | 12(N/A) | meal | |
| 200 solution | 8(0.5-48h) | 12(N/A) | meal | |
| (Daneshmend 1981) | 200, 400 tablet | 14(0.5 – 48h) | 28-44 6(6/0) | meal |
| (Daneshmend 1983) | 200 tablet, 7(0-24h) | 10(0.5-8h) | 8(8/0) | fasting |
| (Daneshmend 1984) | 200, 400, 600 | 13(0.5, 32h) | 8(3/5) | meal |
| 800, tablet | (20-31) | |||
| (Huang 1986) | 200 solution suspension, tablet | 12(0.5-48h) | 24(24/0) | fasting |
| 200, 400, 800 solution. | 12(0.5-48h) | 12(24/0) | fasting | |
| (FDA 1999) | 200 tablet | 17(1/4-24h) | 39(39/0) | fasting |
| 200 tablet | 17(1/4-24) | 23(24/0) | meal | |
| (FDA 1999) | 200 tablet | 15(1/3-48) | 24(24/0) | fasting |
| 200 tablet | 15(1/3-48) | 17(17/0) | meal | |
| MDZ : | ||||
| (Lee 2002)† | 2 IV | 27(1/2-6h) | 12(6/6) | fasting |
| (Tsunoda 1999) | 2 IV | 12(1/4-8h) | 9(6/3) | fasting |
†
In the original paper, MDZ was through IV fusion in a very short period to 2mg, we used the portion of data after fusion and assume IV bolus administration.